Cadrenal Therapeutics, Inc. Common Stock

CVKDNASDAQ • USD
4.64 USD
↘ 0.07 (1.38%)🟢LIVE (AS OF 01:23 PM EDT)
🟢Market: OPEN
Open?$4.67
High?$4.73
Low?$4.61
Prev. Close?$4.70
Volume?7.8K
Avg. Volume?57.4K
VWAP?$4.67
Rel. Volume?0.14x
Bid / Ask
Bid?$4.28 × 100
Ask?$4.51 × 100
Spread?$0.23
Midpoint?$4.40
Valuation & Ratios
Market Cap?11.0M
Shares Out?2.3M
Float?1.8M
Float %?76.1%
P/E Ratio?N/A
P/B Ratio?4.01
EPS?-$5.66
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.72Strong
Quick Ratio?2.72Strong
Cash Ratio?2.52Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
83/100
P/E?
N/A▾
P/B?
4.01FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
-0.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
-483.3%WEAK▾
ROA?
-306.0%WEAK▾
Cash Flow & Enterprise
FCF?$-12606770
Enterprise Value?$7.0M
Related Companies
Loading...
News
Profile
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Employees
4
Market Cap
11.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cadrenal.com
Listed
2023-01-20
Address
822 A1A NORTH
PONTE VEDRA, FL 32082
Phone: 904-300-0701
MarketsMoversWatchlist